Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Advent of PARP Inhibitors in Metastatic CRPC

August 1st 2023

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer

August 1st 2023

Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.

State of Science Summit-Prostate/RCC: Chaired by Ulka N. Vaishampayan, MBBS

August 1st 2023

State of Science Summit-Prostate/RCC: Chaired by Ulka N. Vaishampayan, MBBS

Dr Wise on Key Trials Establishing Treatment Intensification as a SOC in mHSPC

July 31st 2023

David R. Wise, MD, PhD, discusses key trials establishing the benefit of hormone therapy– or chemotherapy-based doublet therapy for patients with metastatic hormone-sensitive prostate cancer

Analysis Helps Distinguish the Molecular Profile of Intraductal Carcinoma of the Prostate

July 31st 2023

Benjamin Miron, MD, explains the purpose of studying the molecular profile of intraductal carcinoma of the prostate, expands on the potential prognostic and targetable alterations identified in patients with this histology, and discusses the planned cohort expansion and analysis of RNA signatures in this population.

EU Approves Piflufolastat (18F) PSMA PET Imaging Agent for Prostate Cancer

July 28th 2023

The European Commission has approved piflufolastat (18F) for the detection of prostate-specific membrane antigen–positive lesions with positron emission tomography in adults with prostate cancer.

Dr Agarwal on Future Questions to Address Following the TALAPRO-2 Trial in mCRPC

July 26th 2023

Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Gaps in Validated Quality Indicator Use Are Evident in Active Surveillance of Low-Risk Prostate Cancer

July 26th 2023

Varied levels of compliance were observed in terms of using validated quality indicators to determine the quality of active surveillance for patients with low-risk prostate cancer, according to findings from a population-based study published in the Journal of the Comprehensive Cancer Network.

NCCN Adds Flotufolastat F 18 Injection to Clinical Practice Guidelines for Prostate Cancer

July 26th 2023

The National Comprehensive Cancer Network has added flotufolastat F 18 injection to its Clinical Practice Guidelines in Oncology for positron emission tomography of prostate-specific membrane antigen–positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy.

Informing Systemic Therapy Selection With Negative Data in HSPC

July 25th 2023

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

What is the Role of Locoregional Therapy in Metastatic HSPC?

July 25th 2023

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

Tinengotinib Elicits Clinical Benefit in Pretreated Cholangiocarcinoma and Other Advanced Solid Tumors

July 24th 2023

Sanjay Goel, MD, MS, expands on the findings from the phase 1b/2 trial, noting the potential benefit this approach may have for patients with cholangiocarcinoma, and detailed next steps for investigating tinengotinib.

FDA Awards Fast Track Designation to ARX517 for Metastatic Castration-Resistant Prostate Cancer

July 20th 2023

The FDA has granted fast track designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer who experience disease progression on an androgen receptor pathway inhibitor.

Dr Miron on the Methods of Examining Molecular Alterations in Intraductal Carcinoma of the Prostate

July 19th 2023

Benjamin Miron, MD, discusses the methods utilized in a study of molecular alterations in patients with intraductal carcinoma of the prostate and the next steps for this research.

Agarwal Discusses FDA Approval of Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 19th 2023

Neeraj Agarwal, MD, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC.

Dr Lowentritt on the Rationale for Investigating Real-World PSA Response to AR Inhibitors in mCSPC

July 18th 2023

Benjamin H. Lowentritt, MD, FACS, discusses the background and rationale for conducting a real-world retrospective study of prostate-specific antigen responses generated from second-generation androgen receptor inhibitors in patients with metastatic castration-sensitive prostate cancer.

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023

Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.

Dr. Tagawa on the Evolution of ADCs in mCRPC

July 14th 2023

Scott Tagawa, MD, MS, FACP, discusses the evolution of antibody-drug conjugates in metastatic castration-resistant prostate cancer, as well as potential future targets for ADC development in this space.

Dr Lowentritt on the Implications of Data on Real-World ASRI Efficacy in mCSPC

July 13th 2023

Benjamin H. Lowentritt, MD, FACS, discusses how results from a real-world retrospective study of responses with second-generation androgen receptor signaling inhibitors in patients with mCSPC could affect the selection and use of next-generation ARSIs in practice, and how this research identifies several other unanswered questions for future investigation.

Olaparib Bolsters Lutetium Lu 177 Vipivotide Tetraxetan Activity in mCRPC

July 11th 2023

Enhanced antitumor activity was shown with the addition of the PARP inhibitor olaparib to the radioligand lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer.